Mind Medicine (MindMed) Inc. (MNMD)
NASDAQ: MNMD · Real-Time Price · USD
5.54
-0.31 (-5.30%)
At close: Apr 1, 2025, 4:00 PM
5.59
+0.05 (0.90%)
After-hours: Apr 1, 2025, 4:26 PM EDT
Company Description
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.
The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Mind Medicine (MindMed) Inc.
Country | United States |
Founded | 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 74 |
CEO | Robert Barrow |
Contact Details
Address: One World Trade Center, Suite 8500 New York, New York 10007 United States | |
Phone | 212 220 6633 |
Website | mindmed.co |
Stock Details
Ticker Symbol | MNMD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001813814 |
CUSIP Number | 60255C109 |
ISIN Number | CA60255C8850 |
SIC Code | 2833 |
Key Executives
Name | Position |
---|---|
Robert Barrow | Chief Executive Officer and Director |
Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer |
Dr. Scott M. Freeman M.D. | Co-Founder and Clinical Advisor |
Leonard Latchman | Co-Founder |
Carrie F. Liao CPA, CGMA | Vice President and Chief Accounting Officer |
Mark R. Sullivan J.D. | Chief Legal Officer and Corporate Secretary |
Stephanie Fagan | Chief Corporate Affairs Officer |
Dr. Gregg Pratt Ph.D. | Chief Regulatory and Quality Assurance Officer |
Matthew Wiley | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 25, 2025 | 144 | Filing |
Mar 25, 2025 | 144 | Filing |
Mar 25, 2025 | 144 | Filing |
Mar 25, 2025 | 144 | Filing |
Mar 6, 2025 | 10-K | Annual Report |
Mar 6, 2025 | 8-K | Current Report |
Feb 5, 2025 | SCHEDULE 13G/A | Filing |
Jan 30, 2025 | 8-K | Current Report |
Jan 13, 2025 | 8-K | Current Report |
Dec 26, 2024 | 144 | Filing |